Statin therapy: Not just used to lower cholesterol?

Critical Care Nursing Quarterly

Volumn 30, Issue 2, 2007, Pages 154-160

  Kronmann, Lisha ^a   Hatfield, Chad ^a   Kronmann, Karl ^b  

^a SCRIPPS MERCY HOSPITAL   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

Acute coronary syndrome; Percutaneous intervention; Sepsis; Statin therapy

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG ELUTING STENT; HUMAN; HYPERLIPIDEMIA; PERCUTANEOUS CORONARY INTERVENTION; PLEIOTROPY; REVIEW; SEPSIS; HYPERCHOLESTEROLEMIA; INFLAMMATION; PATIENT SELECTION; POSTOPERATIVE CARE; PRACTICE GUIDELINE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INFLAMMATION; PATIENT SELECTION; POSTOPERATIVE CARE; PRACTICE GUIDELINES; SEPSIS; TREATMENT OUTCOME;

EID: 34249651453     PISSN: 08879303     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CNQ.0000264258.82875.89     Document Type: Review

References (30)

1. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiological Approach. 6th ed. New York: McGraw Hill; 2005.
2. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006;367:413-418.
3. Walter DH. Insights into early and rapid effects of statin therapy after coronary interventions. Curr Pharma Des. 2004;10:369-373.
4. Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J. 2004;25(20):1822-1828.
5. Pasceri V, Patti F, Nusca A, Pristipino C, Richichi G, DiSciascio G, and ARMYDA investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study. Circulation. 2004;110(6):674-678.
6. Jaschke B, Michaelis C, Milz S, et al. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res. 2005;68(3):483-492.
7. Erl W. Statin-induced vascular smooth muscle cell apoptosis: a possible role in the prevention of restenosis. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:135-144.
8. Almog Y. Statins, inflammation, and sepsis. Chest. 2003;124:740-743.
9. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004;110:880-885.
10. Davies MJ. The pathophysiology of acute coronary syndromes. Heart. 2000;83:361-366.
11. deLemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307-1316.
12. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trail. JAMA. 2001;285:1711-1718.
13. Cannon CP, Braunwald E, McCabe CH, et al, and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
14. Brener SJ, Ellis SG, Schneider J, Topol EJ. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J. 2002;23:869-876.
15. Nallamothu BK, Bates ER. Periprocedural myocardial infarction and mortality. J Am Coll Cardiol. 2003;42(8):1412-1414.
16. Iwata A, Miura S, Shirai K, et al. Lower level of low-density lipoprotein cholesterol by statin prevents progression of coronary restenosis after successful stenting in acute myocardial infarction. Intern Med. 2006;45(15):885-890.
17. Bae JH, Bassenge E, Kim KY, Synn YC, Park KR, Schwemmer M. Effects of low-dose atorvastatin on vascular responses in patients undergoing percutaneous coronary intervention with stenting. J Cardiovasc Pharmacol Ther. 2004;9(3):185-192.
18. Lerakis S, El-Chami MF, Patel AD, et al. Effect of lipid levels and lipid-lowering therapy on restenosis after coronary artery stenting. Am J Med Sci. 2006;331(5):270-273.
19. Sinderman JR, Verin V, Hopewell JW, Rodemann HP, Hendry JH. Biological aspects of radiation and drug-eluting stents for the prevention of restenosis. Cardiovasc Res. 2004;63:22-30.
20. Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention.). Circulation. 2006;113(7):e166-e286.
21. Thom T, Hase N, Rosamond W, et al, for the American Heart Association. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation. 2006;113;e85-e151.
22. Kannel WB, Wilson PW. Comparison of risk profiles for cardiovascular events: implications for prevention. Adv Intern Med. 1997;42:39-66.
23. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. The PURSUIT investigators. Circulation. 2000;101:2557-2567.
24. Grundy S, Cleeman J, Merz B, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
25. Shepherd J, Blauw GJ, Murphy MB, et al, and the PROSPER study group. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomized controlled trial. PROspective Study of Pravastain in the Elderly at Risk. Lancet. 2002;360:1623-1630.
26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals; a randomized placebo-controlled trial. Lancet. 2002;360(9326):7-22.
27. Sever PS, Dahlof B, Poulter NR, et al and ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm(ASCOT-LLA); amulticentre randomized controlled trial. Lancet. 2003;361:1149-1158.
28. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLA). JAMA. 2002;288:2998-3007.
29. Clark LT. Treating dyslipidemia with statins: the risk-benefit profile. Am Heart J. 2003;145(3):387-396.
30. Snow V, Aronson MD, Hornbake R, Mottur-Pilson C, Weiss KB. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2004;140:644-649.